Summary
The influence of renal failure and of hepatic cirrhosis on the plasma protein binding of etomidate, an intravenous anaesthetic agent of basic nature, has been investigated. The percentage of free etomidate in plasma containing 1 μg/ml was markedly increased in patients with renal failure and in patients with hepatic cirrhosis, when compared with a group of healthy volunteers (43.4 ± 2.9% and 44.2 ± 2.1 versus 24.9 ± 1.4%). This decrease in binding correlated inversely with serum albumin levels in both conditions (r = −0.88 and r = −0.72, respectively) but a slight decrease in the amount bound per mole of albumin was also apparent in both types of disease.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Preliminary results presented at the 7th International Congress of Pharmacology, Paris, July 1978.
Rights and permissions
About this article
Cite this article
Carlos, R., Calvo, R. & Erill, S. Plasma Protein Binding of Etomidate in Patients with Renal Failure or Hepatic Cirrhosis. Clin-Pharmacokinet 4, 144–148 (1979). https://doi.org/10.2165/00003088-197904020-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-197904020-00007